Welcome to our dedicated page for Bicycle Therapeutics SEC filings (Ticker: BCYC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hundreds of pages on peptide chemistry, Phase 1 dose-escalation results, and future funding needs make Bicycle Therapeutics� disclosures a challenge. Whether you are searching for Bicycle Therapeutics insider trading Form 4 transactions before a data read-out or trying to gauge cash runway in the next Bicycle Therapeutics quarterly earnings report 10-Q filing, the details are buried in dense biotech language.
Stock Titan solves that problem. Our AI decodes every submission on EDGAR, delivering Bicycle Therapeutics Form 4 insider transactions real-time and presenting Bicycle Therapeutics SEC filings explained simply—from clinical milestones to share-based compensation. You’ll receive concise Bicycle Therapeutics earnings report filing analysis, risk-factor highlights, and plain-English definitions so you can focus on decisions, not document hunting. It’s the fastest path to understanding Bicycle Therapeutics SEC documents with AI.
Need to track management’s confidence? Monitor Bicycle Therapeutics executive stock transactions Form 4. Curious about dilution or runway? Browse the Bicycle Therapeutics annual report 10-K simplified. Evaluating governance? Our platform links directly to the Bicycle Therapeutics proxy statement executive compensation. Material trial updates hit instantly too, with Bicycle Therapeutics 8-K material events explained in minutes. Every filing�10-K, 10-Q, 8-K, S-3, DEF 14A—lands here with AI-powered summaries, real-time alerts, and keyword search so you never miss a pipeline disclosure or funding move. Make informed calls faster, backed by complete, current information.
SEC Form 4 filed for First Guaranty Bancshares, Inc. (FGBI) discloses that director Edgar R. Smith III markedly increased his ownership on 30 June 2025.
- Open-market purchase: 30,865 common shares acquired at $8.10 (Code P).
- Debt-for-equity exchange: 1,981,506 new shares issued at $7.57 in exchange for a $15 million floating-rate subordinated note under an Exchange Agreement dated 16 June 2025.
- Note amendments: 88,482 shares issued at $8.00 to Smith & Tate Investments, LLC pursuant to amendments to an existing promissory note and a subordinated note.
Following these transactions, Smith reports 2,852,467 shares held directly. Indirectly, he controls additional positions through several LLCs, including Smith & Hood Holding Company, LLC (1,062,817 shares) and three other investment entities, taking total reported beneficial ownership well above three million shares.
The filing signals a net addition of roughly 2.1 million shares, replacing interest-bearing debt with equity and reflecting continued insider confidence. Because the new shares were issued below recent market purchases ($7.57 vs. $8.10), the company reduces debt at a valuation apparently acceptable to both parties while the director deepens alignment with common shareholders.
Arhaus, Inc. (NASDAQ: ARHS) filed an 8-K announcing a board change. On 27 June 2025 the Board appointed Samir Desai—currently EVP & Chief Digital and Technology Officer at Abercrombie & Fitch—as an independent Class III director. His initial term runs until the 2027 annual meeting, after which he is expected to stand for re-election. Desai will sit on the Board’s Technology Committee, bringing extensive omnichannel retail and IT leadership experience from Abercrombie & Fitch, Equinox Group and Intertex Apparel Group. To accommodate the appointment, the Board’s size rises from ten to eleven directors. Compensation will mirror that of Arhaus’s other non-employee directors and no related-party transactions were reported. Exhibit 104 (Inline XBRL cover page) accompanies the filing.
Form 4 filing for UnitedHealth Group (UNH) dated 07/02/2025 discloses routine quarterly equity compensation to non-employee director Paul R. Garcia.
- Transactions (07/01/2025): 173 deferred stock units (immediately vested, must be held until board service ends) and 96 shares of common stock, both awarded at $0 cost.
- Post-transaction ownership: 2,750 common shares held directly; 2,146 shares in a revocable trust; 45 and 55 shares in two additional trusts, for a total indirect holding of 2,246 shares.
- No derivative securities were acquired or disposed of; the filing cites the awards as regular quarterly director compensation, not incentive-based or market purchases.
The filing is administrative in nature, with no impact on company operations, capital structure, or insider sentiment beyond customary board compensation.
Triumph Financial, Inc. (TFIN) � Form 4 insider filing
Director Laura Easley reported the July 1, 2025 receipt of 653 fully-vested common shares granted under the company’s 2014 Omnibus Incentive Plan. The award was recorded at $0 cost, indicating a standard equity compensation grant rather than an open-market purchase. Following the transaction, Easley’s direct holdings rose to 8,301 shares. She also reports 1,895 shares held indirectly as trustee of the Easley Family Trust, for total beneficial ownership of 10,196 shares.
No derivative securities were involved, and there were no dispositions. This filing reflects routine board-level compensation and represents a modest increase in insider ownership (approximately 0.04% of TFIN’s 25 million share count, assuming prior public float). While not financially material to the company, insider accumulation can be viewed as a modestly positive governance signal.
MGIC Investment Corp. (MTG) � Form 4 insider transaction
President & COO Salvatore A. Miosi disclosed the sale of 30,000 shares of common stock on 01-Jul-2025 at a weighted-average price of $28.152 per share, generating roughly $0.84 million in proceeds. The disposition was executed under a Rule 10b5-1 trading plan adopted on 06-Mar-2025, indicating the sale was pre-scheduled and not necessarily driven by near-term information.
After the transaction, Miosi directly owns 279,401.361 shares and indirectly controls 384,844 shares via a family trust, maintaining a sizable equity stake. No derivative security activity was reported, and the filing contains no references to earnings, major corporate events, or strategic changes.
The filing primarily records a routine adjustment to the executive’s equity exposure; in isolation, it is unlikely to materially affect the company’s fundamental outlook.
Vimeo, Inc. (VMEO) Form 4 filing dated 07/02/2025 reports that director Lydia Jett received an equity award of 44,444 restricted stock units (RSUs) of common stock on 07/01/2025.
The RSUs vest in two equal installments on the first and second anniversaries of the grant date (22,222 shares each on 07/01/2026 and 07/01/2027). Following the grant, Jett directly beneficially owns 44,444 shares; no shares were sold and no cash price is listed, confirming the award is a standard component of board compensation.
The filing lists no derivative securities and references no Rule 10b5-1 trading plan. From an investor standpoint, the disclosure signals continued alignment of board incentives with shareholder interests but is not expected to have a material impact on Vimeo’s share count, earnings, or valuation given the company’s large outstanding share base.
FAQ
What is the current stock price of Bicycle Therapeutics (BCYC)?
What is the market cap of Bicycle Therapeutics (BCYC)?
What is the primary focus of Bicycle Therapeutics Limited?
How does the Bicycle® platform differentiate from traditional therapies?
In which therapeutic area is the company primarily operating?
What are Bicycle Therapeutics' key geographical segments?
How does Bicycle Therapeutics generate revenue?
What is unique about the therapeutic approach of Bicycle Therapeutics?
How does the technology improve safety profiles in oncology treatments?
How does Bicycle Therapeutics position itself within a competitive biopharmaceutical market?
